423 related articles for article (PubMed ID: 24418325)
21. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
22. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
Lü S; Yang J; Song X; Gong S; Zhou H; Guo L; Song N; Bao X; Chen P; Wang J
J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
[TBL] [Abstract][Full Text] [Related]
23. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Altun M; Galardy PJ; Shringarpure R; Hideshima T; LeBlanc R; Anderson KC; Ploegh HL; Kessler BM
Cancer Res; 2005 Sep; 65(17):7896-901. PubMed ID: 16140960
[TBL] [Abstract][Full Text] [Related]
24. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
[TBL] [Abstract][Full Text] [Related]
25. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
26. Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells.
Woodle ES; Tremblay S; Brailey P; Girnita A; Alloway RR; Aronow B; Dasgupta N; Ebstein F; Kloetzel PM; Lee MJ; Kim KB; Singh H; Driscoll JJ
Am J Transplant; 2020 Feb; 20(2):399-410. PubMed ID: 31595669
[TBL] [Abstract][Full Text] [Related]
27. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
Liu CY; Shiau CW; Kuo HY; Huang HP; Chen MH; Tzeng CH; Chen KF
Haematologica; 2013 May; 98(5):729-38. PubMed ID: 22983581
[TBL] [Abstract][Full Text] [Related]
28. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
Lü S; Yang J; Chen Z; Gong S; Zhou H; Xu X; Wang J
Exp Hematol; 2009 Jul; 37(7):831-7. PubMed ID: 19426847
[TBL] [Abstract][Full Text] [Related]
29. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
[TBL] [Abstract][Full Text] [Related]
30. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
[TBL] [Abstract][Full Text] [Related]
32. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.
Guillaume B; Chapiro J; Stroobant V; Colau D; Van Holle B; Parvizi G; Bousquet-Dubouch MP; Théate I; Parmentier N; Van den Eynde BJ
Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18599-604. PubMed ID: 20937868
[TBL] [Abstract][Full Text] [Related]
33. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
Niewerth D; Kaspers GJ; Jansen G; van Meerloo J; Zweegman S; Jenkins G; Whitlock JA; Hunger SP; Lu X; Alonzo TA; van de Ven PM; Horton TM; Cloos J
J Hematol Oncol; 2016 Sep; 9(1):82. PubMed ID: 27599459
[TBL] [Abstract][Full Text] [Related]
34. Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Niewerth D; Jansen G; Assaraf YG; Zweegman S; Kaspers GJ; Cloos J
Drug Resist Updat; 2015 Jan; 18():18-35. PubMed ID: 25670156
[TBL] [Abstract][Full Text] [Related]
35. (Immuno)proteasomes as therapeutic target in acute leukemia.
Cloos J; Roeten MS; Franke NE; van Meerloo J; Zweegman S; Kaspers GJ; Jansen G
Cancer Metastasis Rev; 2017 Dec; 36(4):599-615. PubMed ID: 29071527
[TBL] [Abstract][Full Text] [Related]
36. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
37. A Cell-Based Platform for the Investigation of Immunoproteasome Subunit β5i Expression and Biology of β5i-Containing Proteasomes.
Burov A; Funikov S; Vagapova E; Dalina A; Rezvykh A; Shyrokova E; Lebedev T; Grigorieva E; Popenko V; Leonova O; Spasskaya D; Spirin P; Prassolov V; Karpov V; Morozov A
Cells; 2021 Nov; 10(11):. PubMed ID: 34831272
[TBL] [Abstract][Full Text] [Related]
38. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
40. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
